Novel methodologies in analysis of small molecule biomarkers and living cells

Chen, Yinan; Zhu, Zhenggang; Yu, Yingyan

doi:10.1007/s13277-014-2439-2

Cited by 5 publications

(6 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GC-MS is widely applied in metabolomics study, which provide a rapid, qualitative and quantitative analyses with the ability to identify small molecule metabolites [29, 30]. GC can separate volatile and thermal stable compounds, then the compounds are eluted and detected by MS. MS is operated by ion formation, separation and detection of ions according to mass-to-charge (m/z) ratio.…”

Section: Introductionmentioning

confidence: 99%

A characteristic biosignature for discrimination of gastric cancer from healthy population by high throughput GC-MS analysis

et al. 2016

Self Cite

View full text Add to dashboard Cite

Early diagnosis of gastric cancer is crucial to improve patient′ outcome. A good biomarker will function in early diagnosis for gastric cancer. In order to find practical and cost-effective biomarkers, we used gas chromatography combined mass spectrometer (GC-MS) to profile urinary metabolites on 293 urine samples. Ninety-four samples are taken as training set, others for validating study. Orthogonal partial least squares discriminant analysis (OPLS-DA), significance analysis of microarray (SAM) and Mann-Whitney U test are used for data analysis. The diagnostic value of urinary metabolites was evaluated by ROC curve. As results, Seventeen metabolites are significantly different between patients and healthy controls in training set. Among them, 14 metabolites show diagnostic value better than classic blood biomarkers by quantitative assay on validation set. Ten of them are amino acids and four are organic metabolites. Importantly, proline, p-cresol and 4-hydroxybenzoic acid disclose outcome-prediction value by means of survival analysis. Therefore, the examination of urinary metabolites is a promising noninvasive strategy for gastric cancer screening.

show abstract

Section: Introductionmentioning

confidence: 99%

A characteristic biosignature for discrimination of gastric cancer from healthy population by high throughput GC-MS analysis

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…118 A microfluidic droplet system has also been developed for highthroughput screening of chemical libraries for discovery of smallmolecule inhibitors with a high-resolution dose-response relationship. 123,124 This study identified numerous inhibitors and indicated a most potent candidate, cefsulodin sodium, exhibiting an half maximal inhibitory concentration (IC50) of 27 ± 0.83 μM.…”

Section: Metabolites and Small-molecule Inhibitors As Affinity Reagentsmentioning

confidence: 99%

Microfluidics in the selection of affinity reagents for the detection of cancer: paving a way towards future diagnostics

Hung

Wang

et al. 2016

Lab Chip

View full text Add to dashboard Cite

Microfluidic technologies have miniaturized a variety of biomedical applications, and these chip-based systems have several significant advantages over their large-scale counterparts. Recently, this technology has been used for automating labor-intensive and time-consuming screening processes, whereby affinity reagents, including aptamers, peptides, antibodies, polysaccharides, glycoproteins, and a variety of small molecules, are used to probe for molecular biomarkers. When compared to conventional methods, the microfluidic approaches are faster, more compact, require considerably smaller quantities of samples and reagents, and can be automated. Furthermore, they allow for more precise control of reaction conditions (e.g., pH, temperature, and shearing forces) such that more efficient screening can be performed. A variety of affinity reagents for targeting cancer cells or cancer biomarkers are now available and will likely replace conventional antibodies. In this review article, the selection of affinity reagents for cancer cells or cancer biomarkers on microfluidic platforms is reviewed with the aim of highlighting the utility of such approaches in cancer diagnostics.

show abstract

“…In DNA, biotin or avidin will link to a DNA fragment. Additionally, this assay can be classified in direct quantitative immuno-PCR, competitive quantitative immuno-PCR, and sandwich quantitative immuno-PCR (Singer et al 2009;Deng et al 2011;Chen et al 2014).…”

Section: Immunoassay System For Immuno-pcrmentioning

confidence: 99%

“…The qiPCR is used for quantification of proteins (Lind & Kubista 2005;Janssen et al 2013), and it was first described by Sims et al (2000). This quantitative system combines the advantages of immunoassays (flexibility and robustness) with the exponential signal amplification power and larger dynamic range of PCR, compared to ELISA (Table 1) (Lind & Kubista 2005;Niemeyer et al 2007;Chen et al 2014). It can be carried out by a gel electrophoresis or qPCR.…”

Section: Quantitative Real-time Immuno-pcr (Qipcr)mentioning

confidence: 99%

“…For many years, the enzyme-linked immunosorbent assay (ELISA) has been used for this purpose. It is a simple, highly sensitive, and easy standardization method; however, ELISA is not suitable for small molecule or trace substance detection (Janssen et al 2013;Chen et al 2014), or some antigens at low concentration (Malou & Raoult 2011). In this way, a new methodology that combines the specificity of the immunological methods, i.e.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immuno-PCR in cancer and non-cancer related diseases: a review

Assumpção

Silva

2016

Veterinary Quarterly

View full text Add to dashboard Cite

Polymerase chain reaction-amplified immunoassay (immuno-PCR, iPCR) is a method that combines the specificity of an immunological detection method and the sensitivity of a nucleic acid amplification method. In this way, immuno-PCR uses a minimum amount of sample, and allows the detection of rare diseases and those diseases in very early stage (i.e. infectious diseases, degenerative disorders, or neoplastic diseases). The present review was aimed to describe this new methodology and applications to the early detection of cancer and noncancer related diseases, and discuss about the possibility to detect diverse biomarkers of oncology disorders, such as breast, gastric, colorectal and nasopharynx cancer, and other factors related to the growth of the neoplastic disease.

show abstract

Novel methodologies in analysis of small molecule biomarkers and living cells

Cited by 5 publications

References 78 publications

A characteristic biosignature for discrimination of gastric cancer from healthy population by high throughput GC-MS analysis

A characteristic biosignature for discrimination of gastric cancer from healthy population by high throughput GC-MS analysis

Microfluidics in the selection of affinity reagents for the detection of cancer: paving a way towards future diagnostics

Immuno-PCR in cancer and non-cancer related diseases: a review

Contact Info

Product

Resources

About